Despite insulin-sensitizing, anti-inflammatory and endothelial protective effects [1–4], adiponectin is an independent positive predictor of cardiovascular (CV) mortality in the general population [5] as well as several clinical sets [6–15] including type 2 diabetes (T2D) [16]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.